Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

Anticancer agent 108 (10 µM; 48 h) significantly inhibited the proliferation of cancer cells [1]. At concentrations of 50, 100, 250, and 500 nM over 72 h, it also suppressed the proliferation of KB-3-1 cells [1]. Moreover, Anticancer agent 108 instigated apoptosis in cells via endoplasmic reticulum (ER) stress at doses of 0.5, 2.5, and 5 µM after 3 and 24 h [1]. Additionally, it induced apoptosis in MDA-MB-231 cells at concentrations of 5 and 10 µM after 24 h [1].

Anticancer agent 108 (administered as a single dose, intraperitoneal injection at 20 mg/kg) does not induce weight loss, rapid demise, leukopenia, anemia, or a reduction in hemoglobin levels in mice.